Expert Video - What targeted therapies are used for people with the EGFR mutation?
Erlotinib, gefitinib, and afatinib are commonly used to treat EGFR mutations in non-small-cell lung cancer, according to Robert Winn, MD, director of the Massey Cancer Center at Virginia Commonwealth University. He also discusses second-line drugs, what happens if patients do not respond to targeted therapies, and how biomarker testing for EGFR and other driver mutations can lead to use of additional targeted therapies for lung cancer.
Share with family and friends:
Click here to take our SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.
This educational activity has been developed by
A Breath of Hope Lung Foundation and Mechanisms in Medicine Inc.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Foundation Inc., Bristol-Myers Squibb Grants and Giving, Foundation Medicine, Genentech, Merck Sharp & Dohme LLC , Neogenomics, Novartis, and Pfizer.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.